Objective: Suppression of ovarian hormones in premenopausal women on gonadotropin-releasing hormone agonist (GnRH AG ) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused by a decline in serum estradiol (E 2 ) is unknown. This study aims to evaluate the effects of GnRH AG with placebo (PL) or E 2 add-back therapy on FM, FFM, and bone mineral density (BMD). Our exploratory aim was to evaluate the effects of resistance exercise training on body composition during the drug intervention.
O besity is a major public health problem in the United States and in developed countries worldwide. Although many behavioral, environmental, and biological factors contribute to the development of obesity, 1 evidence indicates that loss of ovarian hormones increases propensity for weight gain in women. For example, fat mass (FM) increases in response to ovarian hormone suppression in premenopausal women, [2] [3] [4] [5] [6] and estrogen-based hormone therapy (HT) attenuates weight gain in postmenopausal women. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Ovarian hormone deficiency may also alter fat distribution, resulting in a disproportionate increase in abdominal adiposity. 2, 6, 7, 12, 13, 15 Because accumulation of abdominal fat increases the risk of obesity-related diseases (ie, type 2 diabetes mellitus, coronary artery disease, and hypertension), 19 it is important to understand how loss of gonadal function influences regional adiposity and whether this is specifically related to the decline in serum estradiol (E 2 ). E 2 deficiency has well-known adverse effects on bone mineral density (BMD). 20, 21 Less well known is whether E 2 deficiency triggers a decline in lean tissue other than bone, such as skeletal muscle. Suppression of ovarian function in premenopausal women has been observed in some studies to result in a decline in fat-free mass (FFM), 2, 3, 5, 6 but it is not clear whether this is specifically related to the decline in serum E 2 concentration.
Collectively, evidence suggests that the menopausal transition is associated with unfavorable changes in body composition, which include an increase in FM, particularly in the abdominal region, and decreases in FFM and BMD. Because menopause is inextricably associated with age, isolating the independent effects of age or menopause from those of sex hormone deficiency per se is challenging in observational studies, and this underscores the need for controlled studies of the effects of sex hormones on body composition. In this context, the aim of the present study was to evaluate the effects of 5 months of ovarian hormone suppression (gonadotropin-releasing hormone agonist [GnRH AG ]) on body composition (ie, FM, FFM, and BMD) in healthy premenopausal women. To evaluate the mechanistic role of E 2 , we randomized women to receive GnRH AG + placebo (PL) or GnRH AG + E 2 . Our hypothesis was that GnRH AG + PL would increase FM and decrease FFM and BMD and that these changes would be attenuated by E 2 add-back therapy.
If ovarian hormone suppression does result in adverse changes in body composition and BMD, there is little knowledge as to whether such changes can be prevented by exercise training. Therefore, our exploratory aim was to determine whether resistance exercise attenuates the effects of ovarian hormone suppression on body composition and BMD.
METHODS
This was a randomized controlled trial in which premenopausal women were randomized to undergo 5 months of GnRH AG + PL or GnRH AG + E 2 . The study was approved by the Colorado Multiple Institutional Review Board, and all volunteers provided a written informed consent form to participate.
Study participants
Participants were healthy premenopausal women aged 20 to 49 years with normal menstrual cycle function, defined as no missed cycles in the previous year and a mean (SD) cycle length of 28 (5) days. Only nonsmokers were enrolled. Volunteers were screened for eligibility through a review of medical and menstrual cycle history, physical examination, assessment of depressive symptoms, blood chemistry (metabolic panel and complete blood count), measurement of BMD, and a graded exercise test. Exclusion criteria included the following: use of hormonal contraception, oral glucocorticoids, or diabetes medications; history of cardiovascular, renal, or hepatobiliary disease; history of breast cancer, other estrogen-dependent neoplasms, or venous thromboembolic events; uncontrolled thyroid disease (ultrasensitive thyroid stimulating hormone <5 or >10 mU/L); uncontrolled hypertension (systolic blood pressure >150 mm Hg or diastolic blood pressure >90 mm Hg); symptoms of depression (Center for Epidemiologic Studies Depression Scale score !16 or Beck Depression Inventory-II score >18); lactation, pregnancy, or intention to become pregnant; renal dysfunction (serum creatinine >1.3 mg/dL) or hepatic dysfunction (alanine aminotransferase and aspartate aminotransferase >1.5 times the upper limits of normal); hematocrit lower than 33%; proximal femur or lumbar spine BMD T score lower than À2.0; body mass index higher than 39 kg/m 2 ; and abnormal electrocardiogram responses to exercise (confirmed by follow-up evaluation by a cardiologist) that contraindicated vigorous exercise.
Intervention and procedures
Participants underwent baseline testing during days 2 to 6 of the menstrual cycle, although some women were tested later in the follicular phase because of scheduling challenges. GnRH AG therapy (leuprolide acetate 3.75 mg; TAP Pharmaceutical Products Inc, Lake Forest, IL) was initiated at the beginning of the menstrual cycle; subsequent injections were delivered at 4-week intervals for 20 weeks. Absence of pregnancy was confirmed by a urine pregnancy test before each injection.
Participants were randomized to receive transdermal E 2 0.075 mg/day (GnRH AG + E 2 ; Bayer HealthCare Pharmaceuticals, Berkeley, CA) or PL patches (GnRH AG + PL). The E 2 regimen was expected to maintain serum E 2 concentration in the midfollicular phase range. Some participants in each drug group were also randomized to undergo progressive resistance exercise training (GnRH AG + E 2 + Ex, n = 12; GnRH AG + PL + Ex, n = 12). The goal of this exploratory aspect of the study was to generate preliminary data on the effectiveness of exercise in preventing changes in body composition and BMD during ovarian hormone suppression.
Exercise intervention
The progressive resistance exercise intervention included supervised exercise 4 days/week for 18 weeks (ie, ended 2 wk before completion of the GnRH AG intervention), with two sessions per week focused on upper-body exercises (chest press, lat pulldown, overhead press, seated row, and chin-ups/ dips on a weight-assisted machine) and two sessions per week focused on lower-body exercises (leg press, knee extension and flexion, hip abduction and adduction, and squats on a Smith machine). For the first 2 weeks, participants performed three sets of 12 repetitions of each exercise at light intensity to learn how to perform the exercises. On weeks 3 to 6, intensity was increased to approximately 70% of one repetition maximum such that muscle fatigue occurred in 8 to 12 repetitions. Thereafter, intensity was increased to approximately 80% of one repetition maximum (five to eight repetitions per set).
Body composition and BMD
Body composition (total mass, FM, and FFM) and total body, lumbar spine (L1-L4), and proximal femur (total hip, femoral neck, trochanter, and subtrochanter) BMD were measured by dual-energy x-ray absorptiometry (DXA) at baseline and on week 18 of the intervention using a Hologic Discovery-W instrument (software v11.2; Hologic, Waltham, MA). Regional FM and FFM (ie, trunk and leg) measurements were obtained from total body DXA scan. Intra-instrument coefficients of variation for scans completed on women younger than 50 years are as follows: À0.8% total mass, 2.6% FM, 1.1% FFM, 0.8% lumbar spine BMD, 0.9% total hip BMD, 1.9% femoral neck BMD, 1.1% trochanter BMD, and 0.99% subtrochanter BMD. Scans in the current study were completed by two trained and experienced technicians and reviewed by one of the investigators to ensure appropriate data acquisition and image analysis.
Axial CT images were obtained through the center of L2-L3 and L4-L5 intervertebral disc spaces for measurement of abdominal fat areas and at 20 cm superior to the distal edge of the lateral condyle of the right femur for measurement of thigh muscle and fat areas (120 kVp, 200-300 mAs, and 10 mm slice thickness; General Electric Instrument, Waukesha, WI). Images were analyzed by the technicians at the CT Scan Reading Center. Adipose tissue areas were determined using a CT intensity range (À190 to À20 Hounsfield units) that was defined by image-generated histograms of adipose tissue and soft tissue regions. Visceral fat areas (cm 2 ) were manually outlined by tracing the muscles of the abdominal wall. Fat in the bowel was subtracted from the visceral fat area. Subcutaneous fat areas (cm 2 ) were calculated by subtracting the visceral and bowel fat areas from the total abdominal fat area. Thigh muscle area was separated from the subcutaneous fat area by manually tracing along the deep fascial plane surrounding the muscles. Abdominal fat areas were averaged over the two abdominal slices, and thigh muscle areas were averaged over the right and left thigh slices. The threshold for inclusion of repeated thigh scans was AE1 cm of baseline scan location. Analysis programs were developed by the University of Colorado CT Reading Center using IDL software (RSI Inc, Boulder, CO) on a Sparc 20 workstation (Sun Microsystems, Sunnyvale, CA). Scans in the current study were completed by two trained and experienced technicians and reviewed by one of the investigators to ensure appropriate data acquisition and image analysis.
Sex hormones
Blood samples for sex hormones were collected during baseline testing and on week 20 of the intervention. Collection samples were stored at À808C until analysis. Estrone (E 1 ) was determined by radioimmunoassay (Diagnostic Systems Laboratory, Webster, TX) with intra-assay and inter-assay coefficients of variation of 8.7% and 8.6%. E 2 (4.3% and 8.2%), progesterone (4.4% and 7.9%), sex hormone-binding globulin (SHBG; 3.6% and 5.7%) and total testosterone (2.1% and 5.1%) were analyzed by chemiluminescence immunoassay (Access 2 Immunoassay System Analyzer, Beckman Coulter Inc, Fullerton, CA).
Statistical methods
The primary analysis compared the GnRH AG + E 2 and GnRH AG + PL groups, pooled across exercise status. It was acknowledged that the inclusion of exercisers could minimize the effects of GnRH AG but would be reflective of the effects of ovarian hormone suppression on sedentary and active women. Baseline differences in all variables between the GnRH AG + E 2 group and the GnRH AG + PL group were evaluated using two-group t tests, and changes within each group in response to the intervention were evaluated using paired t tests. Differences in changes across time between groups were tested using an analysis of covariance model conditioned on baseline. The study was not powered to detect differences among the four treatment groups for the exploratory exercise intervention aim. Therefore, only descriptive statistics and withingroup changes are presented. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). Data are reported as mean and 95% CI unless otherwise specified.
RESULTS
Seventy-nine women were randomized, and nine participants were lost to follow-up (personal reasons, four participants; lack of time, three participants; adverse effects of GnRH AG , one participant; uncontrolled hypertension, one participant). Of the 70 women who completed the intervention, 35 were randomized to receive GnRH AG + E 2 and 35 were randomized to receive GnRH AG + PL. There were no significant differences in the characteristics of the drug groups at baseline (Table 1) .
Sex hormones
There were significant decreases in serum E 1 , E 2 , progesterone, testosterone, and SHBG in response to GnRH AG + PL. GnRH AG + E 2 resulted in significant decreases in progesterone and testosterone, nonsignificant increases in E 1 and E 2 , and no change in SHBG. The changes in E 1 , E 2 , and SHBG were significantly different between the groups (Table 2) .
Body composition and BMD
There was a decline in FFM in response to GnRH AG + PL that was significantly different from the gain in response to GnRH AG + E 2 ; the loss was distributed across the trunk and leg regions (Table 3 , Fig. 1A) . Thigh muscle area, as measured by CT, decreased after GnRH AG + PL, but not after GnRH AG + E 2 (Fig. 2) . After adjustment for baseline value, there was a difference in the change in thigh muscle area (mean, À3.27 cm 2 ; 95% CI, À5.86 to À0.68; P = 0.01) between the add-back groups.
There were no significant changes in total FM in either drug group (Table 3, Fig. 1A ). However, there were significant increases in both subcutaneous and visceral abdominal fat areas on CT in the GnRH AG + PL group, but not in the GnRH AG + E 2 group (Fig. 2) . Leg fat, as measured by DXA (Table 3 , Fig. 1A) , and thigh fat, as measured by CT (Fig. 2) , did not change. The decreases in spine and hip BMD in response to GnRH AG + PL were significantly different (except Fig. 3A) .
Effects of resistance exercise training
FFM decreased in the GnRH AG + PL + no exercise (NoEx) group, was preserved in the GnRH AG + PL + Ex and GnRH AG + E 2 + NoEx groups, and increased nonsignificantly in the GnRH AG + E 2 + Ex group (Table 4, Fig. 1B ). There were no significant changes in FM in any of the groups, but FM tended to increase in nonexercisers and tended to decrease in exercisers.
BMD decreased at all sites in the GnRH AG + PL + NoEx group, but only at the lumbar spine in the GnRH AG + PL + Ex group (Table 4 , Fig. 3B ). BMD was preserved in all regions in both the GnRH AG + E 2 + NoEx group and the GnRH AG + E 2 + Ex group.
DISCUSSION
The primary aims of this study were to determine whether suppression of ovarian function with GnRH AG adversely affected body composition and BMD and whether changes were specifically related to suppression of E 2 . In support of our hypotheses, we observed that ovarian hormone suppression resulted in decreases in FFM, lumbar spine BMD, and proximal femur BMD that were prevented by E 2 add-back therapy. Unexpectedly, we did not find an increase in FM in response to GnRH AG + PL, as has been observed by others, 2, 3, 5, 6 but there was an increase in abdominal adiposity as measured by CT.
Effects of the drug intervention on FFM
To our knowledge, there have been five previous studies of the effects of GnRH AG therapy (at least 4 mo in duration) on body composition in premenopausal women. 2, 3, 5, 6, 22 Previous studies included women with uterine leiomyoma 2,3,5,6,22 or endometriosis. 5 All of these studies found increases in FM and decreases in FFM, although not all changes were statistically significant. The current study was the first to isolate the role of E 2 in mediating these changes in body composition by randomizing women to GnRH AG + PL versus GnRH AG + E 2 .
The finding that ovarian hormone suppression caused a decrease in FFM was consistent with previous observations. 2, 3, 5, 6 However, because none of the previous studies included E 2 add-back therapy, it was not clear whether the decline in FFM was related to the suppression of estrogens or androgens by GnRH AG . In the current study, there were similar nonsignificant decreases in serum testosterone concentration in both the GnRH AG + PL group and the GnRH AG + E 2 group, but FFM was decreased only in the former. This suggests that the loss of FFM in the GnRH AG + PL group was mechanistically linked with the suppression of E 2 , either through direct actions of E 2 on skeletal muscle or through SHEA ET AL indirect effects of E 2 on other anabolic factors (eg, insulinlike growth factor I). In laboratory animals, estrogens play a key role in the maintenance of skeletal muscle mass and function. 23, 24 Growing evidence indicates that estrogen-based HT helps to preserve muscle mass, strength, and function in postmenopausal women. 23, 25 Muscle mass per se was not measured in the current study, but the changes in thigh muscle area were consistent with the changes in FFM. These findings suggest that the loss of E 2 in women accelerates the loss of muscle mass. Importantly, the use of transdermal E 2 in the current study probably resulted in a smaller decrease in bioavailable androgens than if oral therapy had been used. Oral estrogens were found to increase SHBG and to decrease free testosterone, whereas transdermal E 2 did not. 26 It is not clear whether oral estrogens would be as effective in preserving FFM as transdermal E 2 .
Effects of the drug intervention on FM
Multiple studies of premenopausal women treated with GnRH AG therapy found increases in FM. 2, 3, 5, 6 In these studies, FM increased by 0.9 to 1.9 kg in response to 16 to 24 weeks of GnRH AG therapy. There was also a shift in fat distribution toward abdominal accumulation in response to ovarian hormone suppression, as evidenced by an increase in trunk-to-leg fat ratio after 4 months of GnRH AG therapy. 2, 6 Based on the energy content of fat gains in the four previous studies that involved 16 or 20 weeks of GnRH AG therapy, 2, 3, 5, 6 the magnitude of disruption in energy balance was roughly equivalent to +90 to +130 kcal/day.
Suppression of gonadal hormones also promotes fat gain in men. In healthy men aged 20 to 50 years who underwent 16 weeks of GnRH AG and PL or testosterone add-back therapy, with or without an aromatase inhibitor to block the conversion of testosterone into estrogens, FM increased in men on PL add-back therapy, and this was exaggerated by aromatase inhibition. 27 These findings suggest that E 2 is mechanistically linked with the regulation of energy balance and fat gain in women and men. This is consistent with the observation that estrogen receptor a deficiency causes excess fat gain in both female and male mice. 28 In the current study, we did not observe the increase in total FM that has been observed in other studies of gonadal hormone suppression. 2, 3, 5, 6, 22 A potential factor that may have contributed to the minimal fat gain in the current study was that the consenting process included a discussion of 
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weight gain as a risk of the study. Thus, participants may have been sensitized to the possibility of weight gain and may have compensated by making behavioral changes. This may not have been the case in previous studies of the effects of GnRH AG therapy on body composition because they were observational studies of women undergoing treatment of endometriosis 5 or uterine leiomyomas. 2, 3, 5, 6, 22 The exercise intervention in a subset of participants in the current study also attenuated the magnitude of fat gain. It was not clear whether the previous studies of the effects of GnRH AG therapy on body composition included active and/or sedentary women.
Despite the lack of change in FM in the current study, there were significant increases in both subcutaneous and visceral abdominal fat areas in the GnRH AG + PL group, but not in the GnRH AG + E 2 group. This finding was consistent with the observation that abdominal fat areas, particularly visceral fat areas, increase dramatically during the menopausal transition. 29 It has been observed that the level of abdominal visceral adiposity in women aged 42 to 52 years is linked more closely with androgens than with estrogens, 30 but the current observations suggest that the loss of E 2 triggers the expansion of abdominal fat depots in women.
Effects of the intervention on BMD
As expected, BMD decreased at most skeletal sites in the GnRH AG + PL group, and this was prevented by E 2 . GnRH AG therapy has been observed to cause 4% to 5% decreases in BMD at the lumbar spine after 6 months of treatment. [31] [32] [33] Severity of bone loss depends on GnRH AG dose, length of treatment, and participant characteristics. 34 When duration of treatment is less than 6 months, bone loss is found to be reversible. [35] [36] [37] [38] Effects of the exercise intervention Subsets of women in each drug treatment arm also underwent concurrent resistance training. The intent was to generate preliminary evidence on whether exercise can prevent or attenuate body composition changes that occur in response to ovarian hormone suppression. Because the study was not powered for between-group comparisons, only within-group changes were evaluated. The findings suggest that resistance exercise may be helpful in attenuating the decline in FFM that occurred in response to the suppression of ovarian hormones. Resistance exercise also seemed to mitigate at least some of the decline in BMD at the proximal femur, but not at the lumbar spine. These encouraging preliminary data suggest that regular exercise training may be particularly important during the menopausal transition to minimize bone loss and unfavorable changes in body composition.
A strength of this study was the randomized controlled design, which provided robust experimental control over the sex hormone environment by using pharmacologic suppression of endogenous sex hormones (''medical menopause'') and E 2 or PL add-back therapy. The potential confounding effects of age were minimized by studying premenopausal women. However, the use of the ''medical menopause'' model was also a limitation of the study because it does not simulate all aspects of ''natural menopause'' (eg, more abrupt hormone withdrawal, suppression rather than elevation of gonadotropins). Other limitations were that potential effects of route of E 2 delivery (oral vs transdermal), E 2 dose, or combined E 2 + progesterone add-back therapy were not evaluated.
CONCLUSIONS
Large randomized controlled trials of the risks and benefits of HT in postmenopausal women [39] [40] [41] have increased awareness that the benefits of HT may not outweigh the risks for some women. The current study demonstrates that suppression of ovarian hormones in premenopausal women causes decreases in FFM and BMD and that these changes are specifically related to suppression of E 2 . Our preliminary data further suggest that resistance exercise may help to maintain FFM and BMD during ovarian hormone suppression, but further research will be needed to confirm this potential benefit. It is not clear whether the findings from this study of ovarian hormone suppression in premenopausal women reflect changes that occur in response to the natural menopausal transition. Future studies using this methodologic approach should be carried out in women who are approaching menopause to determine whether there is an independent effect of age.
